ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Endometrial Carcinoma
December 02, 2021Merck and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of advance... -
FDA approves combo drug to treat endometrial carcinoma
September 20, 2019According to the FDA, this review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. -
Eisai, Merck & Co to expand enrolment of study for lenvima, pembrolizumab
September 13, 2017The expansion is based on favourable interim analysis results of the endometrial cohort in a study of lenvatinib in combination with pembrolizumab.
Pharma Sources Insight January 2025
